Contribute Try STAT+ Today

A bill that would allow the Maryland attorney general to take legal action against generic drug makers for price gouging became law on Friday by default, after Governor Lawrence Hogan Jr. declined to sign the legislation over constitutional concerns.

The outcome was praised by consumer activists, who decried a “Wild West” pricing atmosphere, but lambasted by the generic industry trade association, which maintained the law would have a “chilling” effect on competition and “no material impact” on lowering drug costs in the state.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Hmm, I learned that competition leads to LOWER prices and “efficient markets”. Was that a lie? I’m in total shock now!

    Or is there some kind of cartelize market here? Again I’m in total shock!

    One way or the other markets don’t work for pharma. Time for the legislation (and maybe some prosecutors?) to scrub in?

  • Ed, this is classic Whack-A-Mole pharma style. Since most generics are multisource, as soon as Maryland nails one another will emerge.

Comments are closed.